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Abstract
Chronic respiratory symptoms are amongst the most common complaints among low and middle-income country
(LMICs) populations and they are expected to remain common over the 10 to 20 year horizon. The underlying
diseases (predominantly chronic obstructive pulmonary disease, asthma and tuberculosis) cause, and threaten to
increasingly cause, substantial morbidity and mortality. Effective treatment is available for these conditions but
LMICs health systems are not well set up to provide accessible clinical diagnostic pathways that lead to sustainable
and affordable management plans especially for the chronic non communicable respiratory diseases. There is a
need for clinical and academic capacity building together with well-conducted health systems research to
underpin health service strengthening, policy and decision-making. There is an opportunity to integrate solutions
for improving access to effective care for people with chronic respiratory symptoms with approaches to tackle
other major population health issues that depend on well-functioning health services such as chronic
communicable (e.g. HIV) and non-communicable (e.g. cardiovascular and metabolic) diseases.
Introduction
Chronic respiratory diseases are common causes of mor-
bidity among poor populations across the world, with
breathlessness, chest tightness, coughing and wheezing
being the main symptoms. The non-communicable air-
ways diseases chronic obstructive pulmonary disease
(COPD), asthma and - to a lesser extent - bronchiectasis
dominate the picture. However other conditions includ-
ing malignancies, such as bronchogenic carcinoma,
Kaposi’s sarcoma and mesothelioma, can cause chronic
respiratory symptoms and their burden is poorly defined
in most LMICs. Chronic respiratory symptoms can also
be caused by infections, e.g. tuberculosis (TB), and their
clinical presentation overlaps with non-communicable
airways diseases. This overlap is especially important in
LMICs where tuberculosis is common, as the diagnosis
and management differ, and patients with chronic
respiratory diseases are often managed with an incom-
plete diagnostic pathway.
This discussion paper will focus on the non-commu-
nicable chronic airways diseases and their interface with
TB in LMICs. These conditions represent a major burden
of disease and their public health importance is expected
to increase in the next two decades. Although focused on
chronic respiratory diseases, the health systems consid-
erations presented here could apply to other chronic
non-communicable diseases and the potential to identify
health system synergies for their combined management
needs to be considered.
The burden of airways diseases
COPD and asthma are the two of the most common
chronic diseases worldwide, with 80 million people hav-
ing COPD and 235 million estimated to have asthma
worldwide [1]. In 2005 three million people died from
COPD alone, making this condition the fifth leading
cause of adult death. The burden of these diseases is
also increasing, and COPD is expected to be the third
leading cause of death by 2030 [2].
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In addition to causing a high death burden, COPD
and asthma result in significant morbidity, with persis-
tent symptoms, reduced lung function and intermittent
exacerbations adversely affecting functional status and
quality of life.
The distribution of COPD varies around the world
and factors such as the prevalence of smoking and
population age distribution are associated with its preva-
lence. For example, Cape Town has a particularly high
prevalence of COPD, very high smoking rates, high
levels of occupational exposures and TB [3].
The increasingly high rates of smoking in some
LMICs like China and South East Asia, together with
increasing drivers of COPD like air pollution, biomass
fuel use, crowding and ageing populations will make
COPD a major health issue in the next decades. Smok-
ing rates are expanding in most LMICs, even in areas
with relatively low prevalence – particularly in Sub
Saharan Africa – and the world faces an ongoing high
risk from the smoking epidemic.
The distribution of asthma also varies worldwide, from
0.8% in Tibet and 2.4% in India to 32.6% amongst ado-
lescents in New Zealand and 37.6% in Costa Rica. These
variations can also be observed between urban and rural
areas for reasons that are not well understood and may
reflect differences in early life exposure to infections,
allergens and air pollution. Although asthma is more
common in affluent settings, symptoms are usually
more severe in less affluent settings [4].
Bronchiectasis is less common than COPD and
asthma, but causes chronic morbidity with intermittent
exacerbations associated with infections. The global bur-
den of this syndrome is poorly documented due to the
limited access to diagnostic radiology, including High
Resolution Computed Tomography (HRCT) in LMIC
populations. HRCT has become a standard of care in
the evaluation of people with bronchiectasis in well-
resourced healthcare settings, this is likely to be some
decades away in poor resourced settings where other
priorities are likely to come first.
The high burden of ill health caused by chronic respira-
tory diseases in LMICs is accompanied by a high burden
of tuberculosis too. It is also estimated that in 2012 there
were 8.6 million new TB cases with 0.94 million deaths
around the world [5]. TB control is the focus of major
international and national control programmes and con-
sequently receives substantially more funding in LMICs
than all other chronic respiratory diseases combined.
National TB programmes are universally available in
LMIC, are organized as vertical programmes and receive
funding from National budget allocations and interna-
tional funders. The TB diagnostic pathway mostly
screens patients using smear microscopy and this is often
the only diagnostic approach available for patients with
chronic respiratory symptoms. Although current diag-
nostics confirm the presence of TB in about 10-20% of
patients screened, the 80-90% of patients with negative
tests are left without a clear diagnosis. This group of
patients is often repeatedly screened with further TB
tests, empirically diagnosed as having TB and therefore
inadequately treated [CAHRD Paper LH Costs]. There
is thus a substantial number of individuals who receive
the wrong diagnosis; and there is no clear pathway for
the management of patients who are diagnosed as not
having TB.
Obstacles to accessing effective care
Many factors impede people with chronic respiratory
symptoms gaining access to effective care. These could
be considered at the individual, societal and health sys-
tem levels and are better documented for TB than for
other CRDs:
Individual factors
A major obstacle to accessing effective care is the lack of
awareness of the disease. For example, smokers often
expect to have chronic respiratory symptoms and believe
having these symptoms is ‘normal’. There is a wide range
of population concepts of illness, including local ethno-
medical models that may not easily accommodate
concepts of chronicity and ‘incurability’ [6]. This is often
followed by a wide variety of ways in which different cul-
tures organize themselves toward medical treatment.
To attend a health service, an individual needs to
recognize the symptoms are abnormal, that symptoms
are sufficiently severe to warrant attention and to per-
ceive the gains of seeking help are greater than the
costs involved. Decision-making processes are influ-
enced by many factors, including gender, age, disability,
socioeconomic status and others. For example, elderly
individuals with chronic respiratory symptoms may
adjust their lifestyle and attribute their symptoms to
‘age’, considering that nothing can be done or that the
symptoms are not worth treating. Value judgments can
be gender-aligned e.g. young married women or dis-
abled people may feel discouraged to place value on
their own health [7] or access services; masculinities in
some contexts can also mitigate against seeking health-
care [8,9]. Even where care is sought and a diagnosis is
achieved, chronic illness can continue to cause disrup-
tion to physical capabilities, social identity and life tra-
jectory, all of which pose challenges for long-term
management of illness and require a holistic approach
to providing care [10]. For example a study of percep-
tions and experiences of adults and children with
asthma in rural South Africa found significant psycho-
logical impacts including high levels of fear and embar-
rassment [11].
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Societal factors
Chronic respiratory symptoms - especially chronic pro-
ductive cough - is often associated with stigma and
assumed to be TB. TB has a high level of stigma that
differentially affects women and men in different con-
texts depending on factors such as whether they are
married or not [12,13]. There are also high levels of
stigma towards people with asthma who are often reluc-
tant to accept their diagnosis. In Sudan, patients prefer
to regard their condition as an allergy, with a high use
of treatment inhalers and frequent admission to emer-
gency rooms coupled with a very low use of preventer
treatment. There is a common belief that the use of pre-
venters leads to drug dependency and this impacts on
marriage prospects and family reputation [14].
In settings with high HIV prevalence, a diagnosis of TB
is often associated with HIV adding another layer of
stigma [15-17]. In settings where tobacco smoking is
common there can be a society ‘lack of sympathy’ for
individuals with chronic respiratory symptoms who have
‘brought these on themselves’. These societal attitudes
may discourage health-seeking behaviour. Furthermore
social support has been identified as important to the
effective management of chronic illness but the demands
on carers and increased dependence by individuals
experiencing chronic disease may place strains on family
relations, jeopardizing their support [10,18].
Health system factors
To provide effective care for patients with chronic
respiratory symptoms a health system needs to be in
place that is 1) accessible for people in need in an equita-
ble way, 2) adequately staffed by skilled healthcare work-
ers, 3) responsive to health systems information, 4)
adequately resourced in terms of medical products and
treatments for the delivery of chronic disease and
exacerbation management, 5) affordable and 6) led and
governed strategically. Figure 1
Accessibility (geographic, direct and indirect costs and
social)
The individuals most in need of healthcare for chronic
respiratory disease are often those who are disadvan-
taged on other fronts (e.g. poverty, disability, other
forms of marginalization including living in remote
areas), often in a way that is related to the underlying
disease. For example, a woman who develops COPD as
a result of her lifetime exposure to biomass smoke, who
is responsible for attending to crops and looking after
children, may face difficulties accessing care because of
her specific roles in the family, a lack of decision making
power and status and a lack of access to or control over
funds to travel to seek care. A young man disabled by
severe breathlessness, wheezing and coughing may face
a different set of disability-driven challenges including
limited educational and employment opportunities.
Looking over the 10 to 20 year horizon, health systems
will need to provide point of access services as close to
the community as possible [CAHRD paper HS CTC]
and systems will need to increase equity of access.
Information
Although most people with COPD and asthma live and
die in low income settings [2], much of the research
relating to these diseases focuses on high-income coun-
tries. International research programmes, particularly
the BOLD and ISAAC initiatives have made important
steps towards addressing this knowledge gap, but some
areas, notably sub Saharan Africa, have been historically
under-represented [3,4].
Bronchiectasis could be considered a neglected disease
from both a service and a research perspective. There
Figure 1 The WHO Health System Framework
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are few data about the burden of disease in LMICs and
limited evidence to guide practice.
The lack of academic capacity and funding for
research can make building the evidence base around
the epidemiology and management of CRDs most
challenging.
Human resources
Healthcare workers with appropriate knowledge and
skills are needed to deliver care to people with chronic
respiratory symptoms. This knowledge and skills will
need to cover the clinical assessment of patients, the con-
duct and interpretation of investigations and the institu-
tion of a management plan. Self-management approaches
are important for the management of many of these
long-term conditions their degree of control is variable
over time. The ability to communicate effectively with
patients (overcoming educational, social and linguistic
barriers) about their condition and treatment is another
important skill set in this context where partnership
between clients and providers is often central to success.
Many patients will need support managing the identity
transition to being a person with a chronic illness or with
a controlled long-term health condition that requires reg-
ular treatment [19].
The ability of individuals to competently undertake
specific roles is more important than job position; some
of these roles could be undertaken by individuals with-
out formal qualifications who are closer to the commu-
nities [CAHRD paper HS CTC].
Offering treatment and support close to communities is
important to reduce the direct and indirect costs of disease
management to the individual and the household. CTC
providers also offer advantages through their social proxi-
mity in supporting individuals with the social dimensions
of chronic illness [CAHRD paper HS Capacity].
Medical products
Effective care of chronic respiratory diseases requires
access to equipment and consumables needed to make
and monitor diagnoses - particularly sputum examina-
tion and culture, assessment of airway physiology using
peak flow meters and spirometers, chest X-rays and
HRCT. Access to sputum examination and culture is
especially important in the diagnostic evaluation of a
patient with chronic cough and in the evaluation of
patients with bronchiectasis and frequent infective
exacerbations in whom less commonly encountered
micro-organisms like pseudomonas can drive the pro-
cess. Spirometry is essential to secure a diagnosis of
COPD and is useful in the evaluation of patients with
asthma. HRCT imaging is most useful for making the
diagnoses of bronchiectasis and emphysema.
These diagnostic and monitoring technologies how-
ever are often unavailable in LMICs and when available,
they are often unaffordable, poorly-maintained and lack
quality control processes [20]. Where unavailable, prag-
matic approaches to diagnostic and management deci-
sion-making have to be used, but these decision can be
inaccurate and less efficient, especially where long-term
treatments are initiated for incorrect diagnoses.
Service delivery: treatments
The lack of availability of basic effective treatments for
airways diseases is a key factor limiting the management
of these conditions. The essential treatments in them-
selves are relatively straightforward as are guidelines for
their use [21]. Effective chronic disease management of
all the conditions requires education and partnership to
ensure avoidance of triggers (e.g. allergens) and disease
drivers (e.g. exposure to tobacco and other biomass
smoke), sputum clearance, correct use of medication,
monitoring of the disease and prompt institution of
action plans in the event of exacerbation and ongoing
supplies of medication that often needs to continue life-
long. These interventions require health promotion in its
widest sense including ‘structural interventions’ to
address the underlying drivers of health risks, since the
poorest and most marginalized may be those least able to
make choices and to avoid triggers or drivers of disease
[22] [CAHRD Paper LH Biomass].
In terms of medication, all the chronic airways dis-
eases can benefit from access to short-acting inhaled
bronchodilators with the inhaled corticosteroid forming
the cornerstone of asthma management. Access to oral
corticosteroids, inhaled bronchodilators, oxygen and
antibiotics is needed for effective treatment of exacerba-
tions. There are important uncertainties in the detail
such as the efficacy of treatments developed for smok-
ing-related COPD in non-smokers with COPD but in
terms of getting to the point of having access to basic
effective treatments it is probably reasonable to largely
extrapolate from existing (e.g. tobacco) literature
[CAHRD Paper LH Biomass]. One could therefore con-
clude that from a treatment perspective, there already
exist simple effective treatments and as such the devel-
opment of new treatments (unless substantially more
affordable) is less important than matching current and
projected needs with currently available treatments in a
sustainable way. The latter is arguably the key challenge
for the management of airways diseases over the 10 to
20 year horizon.
Healthcare financing
Affordability is a critical determinant of access to inves-
tigations and treatment for people with airways diseases.
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The figure below from the Global Asthma Report 2011
illustrates the affordability of a month ’s supply of
inhaled corticosteroid for asthma purchased from a pri-
vate pharmacy presented as the number of days of
wages required to purchase one inhaler: Figure 2
The month on month ongoing out of pocket costs of
just one inhaler can be substantial and to the point of
representing a catastrophic expenditure from the house-
hold’s perspective. Individuals facing such costs may
find themselves stuck between such high costs for an
effective treatment on the one hand vs continuing to
suffer ongoing chronic symptoms and a risk of exacer-
bations on the other [CAHRD Paper LH Costs]. Provi-
sion for such ongoing healthcare costs needs to be
made explicitly in the design of health financing modal-
ities such as social health insurance policies and essen-
tial healthcare packages, to ensure equity in universal
healthcare coverage. Careful consideration of the priori-
ties for getting maximum benefit for the least cost for
the poorest people with chronic respiratory symptoms
will also be needed
Leadership/Governance
The development of a strategic policy framework is
required to enable the systematic strengthening of
health systems to deliver improved care for chronic
respiratory illnesses. The development of concrete
chronic disease policies and oversight has been identi-
fied as an important element of developing effective
chronic disease interventions [6]. The involvement of
civil society, for example in the form of patient advocacy
and support groups is likely to significantly shape the
effectiveness of interventions and equity in outcomes
[6].
Towards solutions: the 10 to 20 year horizon
A challenge for CAHRD over the 10 to 20 year horizon
is to deliver on its mission to transform health systems
to improve the health of LMIC populations. The vision
of a healthy future for low and middle-income popula-
tions should be realized in this timeframe.
In contrast to other neglected conditions, such as the
Neglected Tropical Diseases [CAHRD Papers NTD
Tools, Models, Delivery], basic diagnostic tools and treat-
ments for chronic respiratory diseases have been avail-
able for decades. The immediate priority therefore is to
match current diagnostics and treatments with the peo-
ple most in need of them. This will require a step change
in the implementation of health systems that overcome
the obstacles to access diagnosis and treatment and mini-
mize the social and economic costs of accessing care.
There are many health system approaches that could be
shared to manage chronic non-communicable (especially
diabetes, heart disease and stroke), infective (especially
HIV) and chronic respiratory diseases. There is thus a
large opportunity to develop integrated approaches for the
efficient management of chronic respiratory and non-com-
municable chronic diseases together with more traditional
vertical programs such as TB, malaria and HIV. Such inte-
grated approaches would build on the 2015 development
goals and would be consistent with the vision of Universal
Health Care
A health system responsive to the needs of patients
with chronic diseases will require provision for the
Figure 2 Global Asthma Report 2011 Healthcare finance graph
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management of acute situations, when the control of the
underlying condition is lost. Acute exacerbations are
common with airways diseases; patients with diabetes
experience hypo and hyperglycaemic emergencies and
patients with ischaemic heart disease and cerebrovascu-
lar disease can suffer myocardial infarction and strokes.
Similar parallels can be drawn with the management of
HIV, with life-long treatment punctuated by the emer-
gence of acute complications such as opportunistic
infections and drug resistance.
Health services management of these chronic diseases
will need to be located within a multi-faceted and multi-
institutional framework, enabling intervention and colla-
boration across structural, community and individual
levels; for example between policy makers, industry, the
media, community organisations such as patient advo-
cacy and support groups, and individual patients [6].
To reach the objective of developing effective and
affordable health systems responsive to the management
of chronic respiratory diseases will require informed pol-
icy and decision-making. However the evidence base to
generate these policies and to inform the structures of a
health system that are needed for their management is
weak. These weaknesses herein constitute a strategic
opportunity for CAHRD to conduct health systems
research to develop innovative approaches and inform
the processes. For this to be a success there will be a
need to strong South-North and South-South collabora-
tion and capacity strengthening for multi-disciplinary
research and service delivery.
All of these activities will need to take place in a chan-
ging world where increasingly health issues are shared
and converging. There has never been a greater opportu-
nity to improve the health and well-being of people living
in LMICs for the benefit of all as part of what has been
coined the Grand Convergence between populations
across the world.
Research opportunities
There is a need for epidemiological studies to determine
the community burden of chronic respiratory diseases in
LMICs and to understand the underlying causes of these
conditions. CAHRD investigators (through LSTM and
MLW collaborations and a public-private partnership
with GlaxoSmithKline) are currently conducting rural
and urban BOLD studies in Malawi. These include stu-
dies to understand the impact of household air pollution
on the decline in lung function over time. However more
studies, including populations with different epidemiolo-
gical characteristics are needed. Burden of disease studies
should include sub-studies on the social and economic
costs of disease and treatment to guide resource alloca-
tion. Studies of chronic respiratory diseases could be
integrated within studies for other chronic diseases; and
integrated approaches to improving population health
should be encouraged.
Health systems research is needed to generate solutions
to obstacles to access health care. These studies should
focus on the poorest and most vulnerable populations of
LMIC who are often less likely to benefit by health sys-
tem improvements driven by more affluent sectors of
society. Herein lies the importance of exploring the effec-
tiveness and cost effectiveness of close-to-community
interventions that reach out to these groups. CAHRD has
a strong presence in this area. For example, the Triage
study in Malawi and Sudan focused on CTC involvement
in TB and HIV referral and follow on Triage Plus studies,
which focus on CTCs and respiratory diseases, are under-
way. Studies in Ethiopia have demonstrated that CTC
approaches can significantly increase and improve access
to TB diagnosis and treatment and have been declared
trail finder approaches by the WHO and the Health
Assembly [CAHRD paper HS CTC].
Studies that facilitate understanding the barriers to
accessing care, and achieving long-term management of
a variety of chronic health conditions and social groups,
are needed to ensure that services are appropriately
designed, acceptable and tailored to the needs of stake-
holders. Such studies will need to include explorations
of the ‘social logic’ of illness conceptualization and how
individuals act to manage their conditions within speci-
fic social contexts [19]. Qualitative studies and eHealth
studies should facilitate the design of effective commu-
nication around long-term disease and exacerbation
management and outcome and process evaluations of
complex health systems interventions are needed.
Conclusions
Chronic respiratory diseases are major global health pro-
blems causing substantial morbidity and mortality and
their burden will increase over the 10 to 20 year horizon.
Many individual, societal and economic obstacles prevent
poor populations with chronic respiratory symptoms
accessing effective health care. Health systems are inade-
quately resourced and developed to respond to the needs
of these conditions. Solutions to address these obstacles
are feasible but require the development of an evidence
base to inform effective and implementable policy and
decision-making. Research and health system capacity
strengthening are essential building blocks to achieving
the vision of improving the health of LMICs.
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